Takeda gains FDA nod for first-in-class narcolepsy treatment Orzeyful

After coming up short with two OX2R agonists, Takeda has scored with oveporexton, gaining FDA approval for the first-in-class drug as a treatment for adults with narcolepsy type 1. Orzeyful, as it will be known commercially, becomes the first medicine to address the root cause of narcolepsy.